Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM -0.35%72 EV-to-EBIT is -244.30 as of Jul. 27, 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.02 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 341 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 293254.84% on this metric.
The historical rank and industry rank for Orion Pharma's EV-to-EBIT or its related term are showing as below:
DHA:ORIONPHARM'
s EV-to-EBIT Range Over the Past 10 Years
Min: -645.06 Med: 18.21 Max: 600.58
Current: -244.3
During the past 12 years, the highest EV-to-EBIT of Orion Pharma was 600.58. The lowest was -645.06. And the median was 18.21.
DHA:ORIONPHARM's EV-to-EBIT is ranked worse than 100% of 341
companies
in the Utilities - Independent Power Producers industry
Industry Median: 17.61
vs DHA:ORIONPHARM: -244.30
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Orion Pharma's Enterprise Value for the quarter that ended in Mar. 2026 was BDT35,064 Mil.
Orion Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-143 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma EV-to-EBIT Related Terms
Orion Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Orion Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: EV-to-EBIT Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma EV-to-EBIT vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Orion Pharma's EV-to-EBIT falls into.
Orion Pharma's current Enterprise Value is BDT35,040 Mil.
Orion Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-143 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a EV-to-EBIT of -244.30 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #999999 out of 341 companies in the Utilities - Independent Power Producers industry.
Is Orion Pharma's EV-to-EBIT too high?
Orion Pharma's current EV-to-EBIT is -244.30. Based on the distribution chart, Orion Pharma ranks #999999 out of 341 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's EV-to-EBIT compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #999999 out of 341 companies for EV-to-EBIT. This places Orion Pharma in the lower half of its industry. The industry median EV-to-EBIT is 17.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for an Utilities - Independent Power Producers company?
The median EV-to-EBIT among Utilities - Independent Power Producers companies is 17.61, based on 341 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median EV-to-EBIT is 17.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current EV-to-EBIT is -244.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.02, compared to a current price of BDT28.70 — trading 43.4% above its estimated fair value. The current EV-to-EBIT is -244.30. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current EV-to-EBIT is -244.30 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.70 is trading 43.4% above its estimated GF Value™ of BDT20.02.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
EV-to-EBIT: -244.30
GF Value™: BDT20.02 vs. price of BDT28.70 (43.4% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
